- cafead Jun 13, 2020 at 11:52: PM
via AbbVie and Roche’s Venclexta has struggled to significantly prolong acute myeloid leukemia (AML) patients’ lives when coupled with a certain type of chemo. But not azacitidine.
Adding Venclexta to azacitidine slashed the risk of death by 34% among previously untreated patients, the partners said Saturday at the European Hematology Association’s virtual annual congress.
article source
Adding Venclexta to azacitidine slashed the risk of death by 34% among previously untreated patients, the partners said Saturday at the European Hematology Association’s virtual annual congress.
article source